… yet unknown viruses, are able to reach the central nervous system and remain latent by hiding in neurons, thereby escaping detection from the immune system. Recurrent reactivation during aging triggers an …

… disease (PD). We propose to develop a gene therapy system that will allow us to reduce the activity of the … therapy and peripheral organs and assess how the immune system responds to the treatment. Impact on …

… of neural networks to molecular and biomolecular systems. He has made over 200 presentations at regional, … in computer modeling techniques of atomic and molecular systems for the elucidation of their chemical and physical …

… between these mutations and the pre-synaptic dopaminergic system or the brain metabolic activity. We aim to … brain metabolism and the pre-synaptic dopaminergic system while exploring the added value of FDG PET in the … the LRRK2 and GBA genes and the pre-synaptic dopaminergic system and whole brain metabolic activity mainly because …

… blood-brain barrier (BBB) allows only a small fraction of systemically administered small-molecule drugs and even … developed for disorders of the central nervous system (CNS) to reach therapeutic concentrations in the … we will employ the SynchroMed II® implantable infusion system and manipulate a variety of infusion parameters to …

… to treat Parkinson’s that don’t focus on the dopamine system. Other so-called “non-dopaminergic” drug candidates … from Addex Therapeutics, targets the brain’s glutamate system to limit dyskinesia in people with PD.  Pimavanserin … from Acadia Pharmaceuticals, targets the brain’s serotonin system in treating the psychosis that is sometimes a side …